ESMO E-Learning: Clinical Cases in Pancreatic Cancer: Adherence to the ESMO Clinical Practice Guidelines
- To provide an update on diagnostic work up and staging of pancreatic cancer.
- To provide an update on optimal adjuvant treatment after surgery in curative intent for resectable pancreatic cancer.
- To provide an update on treatment strategies in locally advanced pancreatic cancer.
This presentation has been developed with the purpose of discussing clinical perspective and enhancing practice implementation of the new ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of pancreatic cancer.
The module consists of two particular patient cases: the first case describes the clinical scenario and the optimal adjuvant treatment in a patient with early stage pancreatic cancer and the second deals with the disease evolution and treatment strategies in a patient with locally advanced disease.
Pancreatic cancer is one of the most highly fatal cancers, with the majority of those affected dying of their disease. Even when diagnosed early, pancreatic cancer often has a poor prognosis. It typically spreads rapidly and is seldom detected in its early stages. Signs and symptoms may not appear until the cancer is quite advanced and surgical removal is not possible. The treatment of pancreatic cancer is challenging with some recent hints of progress.
The two clinical cases presented in this E-Learning module discuss factors that determine diagnosis, staging and adherence to therapy, including evidence-based management strategies. The module presents facts included in the latest revision of the ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up of pancreatic cancer. Aiming to enhance experience with guidelines material, we strongly recommend oncology professionals to refer to the full version of the text available in the May 2010 Supplement of the Annals of Oncology, as well as to the Clinical Practice Guidelines section.
The author has received honoraria for scientific presentations from Roche and Lilly and Research funding from Roche